AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines.
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their rece
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.
AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.